Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease.
Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease.
复制标题
厄贝沙坦是一种 1 型血管紧张素受体抑制剂，可调节冠状动脉疾病患者的血管氧化状态。
DOI：
10.1016/s0735-1097(01)01615-1
复制
发表时间：
2001
影响因子：
24
通讯作者：
Parthasarathy,S
中科院分区：
文献类型：
--
作者：
Khan,BV;Navalkar,S;Khan,QA;Rahman,ST;Parthasarathy,S
目的 本研究的目的是确定血管紧张素 II 1 型 (AT1) 受体拮抗剂对动脉粥样硬化发病机制中观察到的促氧化剂种类的影响。在 AT1 受体拮抗剂厄贝沙坦存在的情况下检查低密度脂蛋白 (LDL) 敏感性、单核细胞结合能力、超氧化物生成和脂质过氧化等参数。背景低密度脂蛋白氧化是动脉粥样硬化过程中的关键组成部分。这种改变可能涉及多种机制，包括一氧化氮水平和超氧化物水平的变化。此外，抑制这些机制的化合物可能会延缓或抑制动脉粥样硬化的发病机制。 方法 47 名患有冠状动脉疾病的患者接受厄贝沙坦治疗 12 周。患者被随机分配接受厄贝沙坦或安慰剂治疗。在第 0、4 和 12 周时测量脂质过氧化、超氧化物水平、单核细胞结合和 LDL 氧化。通过双向重复测量方差分析对结果进行统计学评估，p < 0.05 为显着。结果厄贝沙坦治疗显着降低了我们研究人群中的促氧化环境。 12 周时 LDL 氧化的滞后时间增加了 32%，表明血清中 LDL 修饰的抵抗力增加。硫代巴比妥酸反应物质活性表明，与安慰剂相比，脂质过氧化减少了 36%。此外，接受厄贝沙坦治疗的冠状动脉疾病患者的超氧化物水平和单核细胞结合能力也显着降低。结论我们的结果表明，厄贝沙坦可能通过抑制血管内氧化状态和活性氧的产生来抑制动脉粥样硬化过程，活性氧可能会损害脉管系统。
OBJECTIVESThe aim of this study was to determine the effect of angiotensin II type 1 (AT1) receptor antagonists on pro-oxidant species observed in the pathogenesis of atherosclerosis. Parameters such as low-density lipoprotein (LDL) susceptibility, monocyte binding capacity, superoxide generation and lipid peroxidation were examined in the presence of the AT1receptor antagonist irbesartan.BACKGROUNDLow-density lipoprotein oxidation is a key component in the process of atherogenesis. This modification may involve various mechanisms, including changes in nitric oxide levels and superoxide levels. Additionally, compounds that suppress these mechanisms may retard or inhibit the pathogenesis of atherosclerosis.METHODSForty-seven patients with documented coronary artery disease were treated with irbesartan for a 12-week period. Patients were randomized to receive irbesartan or placebo. Lipid peroxidation, superoxide levels, monocyte binding and LDL oxidation were measured at 0, 4 and 12 weeks. Findings were statistically evaluated by two-way repeated measures analysis of variance with p < 0.05 being significant.RESULTSTreatment with irbesartan significantly decreased the pro-oxidative environment seen in our study population. Lag time for LDL oxidation increased 32% at 12 weeks, suggesting an increased resistance of LDL modification in the serum. Thiobarbituric acid reactive substances activity indicated that lipid peroxidation decreased by 36% in comparison to placebo. In addition, superoxide levels and monocyte-binding capacity were also significantly reduced in coronary artery disease patients receiving irbesartan.CONCLUSIONSOur results indicate that irbesartan may suppress the atherosclerotic process by inhibiting the intravascular oxidative state and the production of reactive oxygen species, compounds that may cause damage to the vasculature.
登录
查看更多内容
影响因子：
15.9
作者：
Rajagopalan, S;Kurz, S;Harrison, DG
通讯作者：
Harrison, DG
长期氯沙坦治疗对易发生中风的自发性高血压大鼠的心脏和血管影响。
影响因子：
8.3
作者：
P. Gohlke;W. Linz;B. Schölkens;G. Wiemer;Thomas Unger
通讯作者：
Thomas Unger
影响因子：
20.1
作者：
GRIENDLING, KK;MINIERI, CA;ALEXANDER, RW
通讯作者：
ALEXANDER, RW
影响因子：
1.7
作者：
J. Wu;L. Wu
通讯作者：
L. Wu
影响因子：
5.3
作者：
KEIDAR, S;KAPLAN, M;AVIRAM, M
通讯作者：
AVIRAM, M